Literature DB >> 33320288

[Histomorphological and molecular-pathological prognostic factors in colorectal cancer].

K Erlenbach-Wünsch1.   

Abstract

Colorectal carcinomas are the second most common cancer and cause of cancer death in Germany for both men and women. Different aspects of morphological, immunohistochemical, and molecular pathological prognostic factors of colorectal carcinomas and their precursors were investigated. We demonstrated the prognostic relevance and importance of a precise classification of pericolonic tumor deposits (PTDs) in the pT category of the TNM classification. Furthermore, we demonstrated that patients with regional lymph node metastases after neoadjuvant chemoradiotherapy (nCRT) in rectal carcinomas with ypN0 status do not have a worse prognosis than patients without signs of preoperative lymph node metastases.Molecular pathological examinations of so-called serrated colorectal fibroblastic polyps as possible precursor lesions of colorectal carcinomas showed that their epithelial area represents a true neoplastic component and thus allows for their consideration in the context of a risk assessment for colorectal carcinomas.

Entities:  

Keywords:  BRAF mutation; Colorectal carcinoma; PTD; Prognostic factors; Prognostic indicators; ypN0

Year:  2020        PMID: 33320288     DOI: 10.1007/s00292-020-00880-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  2 in total

1.  Benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations.

Authors:  Abbas Agaimy; Robert Stoehr; Michael Vieth; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

Review 2.  The origins of colorectal carcinoma: specific nomenclature for different pathways and precursor lesions.

Authors:  Andrea Tannapfel; Matthias Neid; Daniela Aust; Gustavo Baretton
Journal:  Dtsch Arztebl Int       Date:  2010-10-29       Impact factor: 5.594

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.